Li, WeiRisacher, Shannon L.Gao, SujuanBoehm, Stephen L.Elmendorf, Jeffrey S.Saykin, Andrew J.2018-06-082018-06-082017-11-23Li, W., Risacher, S. L., Gao, S., Boehm, S. L., Elmendorf, J. S., & Saykin, A. J. (2017). Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer’s disease biomarker amyloid β1-42 in Alzheimer’s Disease Neuroimaging Initiative participants. Alzheimer’s & Dementia : Diagnosis, Assessment & Disease Monitoring, 10, 94–98. https://doi.org/10.1016/j.dadm.2017.11.0022352-8729https://hdl.handle.net/1805/16456Introduction Type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease. Cerebrospinal fluid (CSF) amyloid β (Aβ) 1-42 is an important Alzheimer's disease biomarker. However, it is inconclusive on how T2DM is related to CSF Aβ1-42. Methods Participants with T2DM were selected from the Alzheimer's Disease Neuroimaging Initiative by searching keywords from the medical history database. A two-way analysis of covariance model was used to analyze how T2DM associates with CSF Aβ1-42 or cerebral cortical Aβ. Results CSF Aβ1-42 was higher in the T2DM group than the nondiabetic group. The inverse relation between CSF Aβ1-42 and cerebral cortical Aβ was independent of T2DM status. Participants with T2DM had a lower cerebral cortical Aβ in anterior cingulate, precuneus, and temporal lobe than controls. Discussion T2DM is positively associated with CSF Aβ1-42 but negatively with cerebral cortical Aβ. The decreased cerebral cortical Aβ associated with T2DM is preferentially located in certain brain regions.en-USAttribution-NonCommercial-NoDerivs 3.0 United StatesAlzheimer's diseaseAmyloid βAβ1-42Cerebrospinal fluid (CSF)Type 2 diabetes mellitusArticle